In a world where companies come and go, only a select few have withstood the test of time, evolving through economic shifts, ...

Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI sepa ...